Valerie Arnold
Child & Adolescent Psychiatry · Memphis, TNNPI 1851358618
Payments from drug & device makers
Across 505 payments — averaging $6885.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.4M
- Sage Therapeutics, LLC$622K
- Supernus Pharmaceuticals, Inc.$397K
- Corium, LLC$371K
- Boehringer Ingelheim$157K
- Shire North American Group Inc$136K
- plus $431K from 16 others
Across 37 payments — averaging $5369.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$193K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Acadia Pharmaceuticals Inc$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Consulting fees$12,41329%
- Speaking & faculty fees$20,94549%
- Travel & lodging$5,47113%
- Food & beverage$4,16410%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | $1,363,076 |
| Sage Therapeutics, LLC | 45 | $622,133 |
| Supernus Pharmaceuticals, Inc. | 92 | $397,022 |
| Corium, LLC | 25 | $371,210 |
| Boehringer Ingelheim | 24 | $157,071 |
| Shire North American Group Inc | 45 | $135,759 |
| Eisai Inc. | 58 | $112,508 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $80,957 |
| Collegium Pharmaceutical, Inc. | 9 | $64,495 |
| Ironshore Pharmaceuticals Inc. | 39 | $43,506 |
| Alkermes, Inc. | 56 | $43,405 |
| Acadia Pharmaceuticals Inc | 13 | $37,389 |
| Rhodes Pharmaceuticals L.p. | 2 | $14,889 |
| AbbVie | 3 | $10,902 |
| Boehringer Ingelheim International GmbH | 45 | $10,011 |
| Sunovion Pharmaceuticals Inc. | 2 | $8,177 |
| Neurocrine Biosciences, Inc. | 1 | $1,975 |
| Vertical Pharmaceuticals, LLC | 1 | $1,600 |
| Jazz Pharmaceuticals Inc. | 1 | $413 |
| Biogen | 5 | $412 |
| Tris Pharma Inc | 3 | $122 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$24,506
- RELEXXII$1,600
- MYDAYIS$1,406
- JORNAY PM$900
How this compares
$3,477,049 in reported general payments places this provider in the 95th percentile of 43 child & adolescent psychiatry providers in Tennessee.
See all child & adolescent psychiatry providers in Tennessee →
Other child & adolescent psychiatry in Memphis
- David StrubleMemphis$4K
- Anthony JacksonMemphis$771
- Adam ChanMemphis$379
- Alicia BarnesMemphis$201
- Ladoris WarrenMemphis$189
- Jonathan ShawMemphis$119
- Allison FordMemphis$86
- Andres Ramos HenriquezMemphis$73
- James MoseleyMemphis$34
- Allyson CundiffNashville$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.